Abstract
Early in the COVID-19 pandemic, SARS-CoV-2 was primarily characterized as a respiratory pathogen. However, emerging clinical evidence soon indicated significant gastrointestinal (GI) involvement. This report details a case from Wuhan, China, where SARS-CoV-2 RNA was identified in the bile of a patient suffering from gallbladder disease, even after respiratory and anal swabs returned negative results. This finding suggests that the biliary system may serve as a viral reservoir, necessitating heightened biosafety protocols during endoscopic procedures.
Introduction
At the onset of the COVID-19 pandemic, diagnostic and safety protocols were heavily weighted toward respiratory transmission. As the virus spread, clinicians began observing non-respiratory symptoms, including diarrhea, nausea, and abdominal pain, suggesting the virus's ability to infiltrate the digestive system. A critical question arose: can SARS-CoV-2 reside in the biliary system? If present in bile, the virus would pose a substantial occupational risk to medical staff performing procedures such as Endoscopic Retrograde Cholangiopancreatography (ERCP). This case study investigates the presence of the virus in non-respiratory fluids to refine infection control and understand the systemic reach of the disease.
Case Presentation and Methods
The study focuses on an elderly female patient in Wuhan, China. Her clinical journey progressed through several diagnostic and interventional stages:
- Initial Diagnosis: In early January 2020, before PCR testing was widely accessible, the patient was diagnosed with COVID-19 based on characteristic "ground-glass opacities" in chest CT scans and supporting blood work.
- Secondary Complications: Two months after the initial infection, the patient developed acute abdominal pain. Magnetic Resonance Cholangiopancreatography (MRCP) revealed choledocholithiasis (gallstones within the bile duct).
- Intervention: To treat the obstruction, the patient underwent an ERCP. During the procedure, a nasobiliary drainage tube was placed to facilitate bile collection and decompression.
- Viral Analysis: Bile samples collected from the drainage tube were analyzed using viral gene sequencing. Additionally, the patient’s systemic immune response was evaluated via Immunoglobulin G (IgG) antibody assays.
Key Results
The investigation yielded several significant findings regarding the localization of the virus:
- Positive Biliary Identification: Viral gene sequencing confirmed the presence of SARS-CoV-2 RNA within the collected bile sample.
- Discordant Testing Results: At the time the bile tested positive, both throat and anal swabs were negative for SARS-CoV-2 via PCR. This indicates that a negative respiratory test is not a definitive indicator of total viral clearance from the body.
- Serological Confirmation: The patient tested positive for SARS-CoV-2 IgG antibodies, confirming a prior systemic infection and immune response.
- Clinical Resolution: Following the ERCP and successful biliary drainage, the patient’s gallbladder symptoms resolved, and she was subsequently discharged.
Discussion and Insights
The identification of SARS-CoV-2 in bile nearly two months after the initial respiratory infection suggests that the biliary tract may act as a site for viral persistence. The exact mechanism of entry remains speculative; the virus may enter the biliary system via the bloodstream (hematogenous spread) or by ascending from the duodenum.
These findings have immediate implications for clinical safety. The presence of viral material in digestive fluids validates the necessity for "Level-3" personal protective equipment (PPE) for GI endoscopy staff. Even in patients who appear recovered based on respiratory metrics, the potential for exposure to infectious material during GI procedures remains a concern.
Limitations and Future Directions
As a single-case study (n=1), these findings do not establish the frequency of biliary involvement in the broader population of COVID-19 patients. Furthermore, while viral genetic material was sequenced, the study did not confirm the presence of live, infectious virus capable of replication.
Future research should focus on:
- Determining the infectivity of SARS-CoV-2 found in bile.
- Investigating the expression of ACE2 receptors—the primary entry point for the virus—within biliary epithelial cells.
- Conducting larger cohort studies to determine if "COVID-19-associated gallbladder disease" represents a distinct clinical entity or a secondary complication of systemic illness.
Summary updated